Selank

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the Zakusov Institute of Pharmacology. It was designed as a stabilized analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that the body produces from the immunoglobulin heavy chain and that plays a role in immune regulation. To make the molecule more resistant to enzymatic breakdown, researchers added a Pro-Gly-Pro sequence to the C-terminus, yielding the final heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro.

This structural modification is central to Selank's identity. Native tuftsin is degraded within seconds to minutes in plasma, which makes it impractical as a therapeutic. The added terminal residues slow enzymatic cleavage and extend the peptide's functional window, allowing it to reach the central nervous system in biologically meaningful amounts, particularly when delivered intranasally. Selank has a molecular weight of roughly 751.88 g/mol and the molecular formula C₃₃H₅₇N₁₁O₉.

In Russia, Selank has been registered and marketed as an anxiolytic, typically as an intranasal solution. This regulatory history sets it apart from most peptides discussed in Western wellness circles, which have never advanced beyond preclinical or early clinical stages. That said, approval in one country does not equal global validation: Selank has not been evaluated or authorized by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and the bulk of its published evidence originates from a relatively small group of Russian research institutions.

If you are new to this class of compounds, our overview of what peptides are explains how short amino acid chains like Selank differ from proteins and small-molecule drugs. Selank belongs to the growing family of "regulatory peptides" — short sequences that act as signaling molecules rather than as structural building blocks, influencing receptors, enzymes, and gene expression at very low doses.

The most studied aspect of Selank's pharmacology is its effect on the GABAergic system — the brain's principal inhibitory neurotransmission pathway. Gamma-aminobutyric acid (GABA) dampens neuronal excitability, and drugs that enhance GABA signaling, such as benzodiazepines, produce anxiolytic and sedative effects. Gene-expression studies in rodents have shown that Selank administration alters the expression of genes involved in GABAergic transmission, including those coding for GABA receptor subunits, suggesting it modulates this system indirectly rather than binding the receptor like a classic drug.

Importantly, Selank does not appear to act as a direct GABA-A receptor agonist in the way benzodiazepines do. Instead, the evidence points to a modulatory role: it appears to influence the balance and turnover of inhibitory signaling while also affecting monoamine neurotransmitters. Research has reported changes in serotonin metabolism and dopamine turnover following Selank exposure, which may contribute to its mood-stabilizing and stress-buffering profile. This multi-target, gentle modulation is often cited as the reason Selank does not produce the pronounced sedation associated with GABA-A agonists.

A second, well-documented mechanism involves the enkephalins — endogenous opioid peptides tied to mood, pain, and stress. Selank has been shown to inhibit the enzymatic degradation of enkephalins in the blood, effectively prolonging their activity. Because enkephalins interact with stress-response and reward pathways, this stabilizing effect may reinforce Selank's anxiolytic and adaptogenic actions. Some researchers describe Selank as an "enkephalin-stabilizing" peptide for this reason.

Selank has also been reported to influence expression of brain-derived neurotrophic factor (BDNF), a protein important for neuronal plasticity and resilience, in specific brain regions such as the hippocampus. Effects on BDNF are frequently proposed as a bridge between the peptide's anxiolytic and cognitive properties. It is worth emphasizing that much of this mechanistic detail comes from animal models, and the precise cascade in humans has not been fully characterized. The picture that emerges is of a broad neuromodulator acting on several systems at once rather than a single, clean molecular target.

Selank's headline application is as an anxiolytic — a compound that reduces anxiety. In Russian clinical practice it has been studied in generalized anxiety disorder (GAD) and neurasthenia, conditions marked by chronic worry, tension, and fatigue. A frequently cited trial by Zozulya and colleagues reported that Selank produced anxiolytic effects comparable to the benzodiazepine medazepam in patients with generalized anxiety and adjustment disorders, while lacking the sedative and amnestic drawbacks typical of that drug class.

The proposed clinical advantage over benzodiazepines is significant if it holds up. Benzodiazepines are effective but carry well-known risks: sedation, cognitive impairment, tolerance, physical dependence, and a difficult withdrawal syndrome. In the available studies, Selank did not appear to cause sedation, and there are no reports of dependence or a withdrawal syndrome after discontinuation. Some researchers have even explored whether Selank could ease benzodiazepine withdrawal, though this remains an early-stage hypothesis rather than an established use.

Preclinical work supports an anxiolytic profile. In classic rodent anxiety models — such as the elevated plus maze and open-field tests — Selank has been reported to reduce anxiety-like behavior and to improve adaptive responses to stress. These findings align with the peptide's origins in the tuftsin family, several members of which influence adaptive behavior under stress conditions.

The important caveat is the strength and independence of the evidence. Human trials have generally been small, conducted in Russia, and not always subjected to the large, placebo-controlled, multi-center replication expected in Western regulatory frameworks. This does not mean the findings are wrong, but it does mean they should be read as promising rather than definitive. Anyone considering Selank for anxiety should first consult a healthcare professional and be aware that established, approved treatments for anxiety disorders exist and have far more robust evidence behind them.

Beyond anxiety, Selank is often discussed as a nootropic — a substance claimed to support cognition, focus, and mental clarity. This reputation stems partly from its neuromodulatory mechanisms and partly from its frequent pairing with Semax, another Russian peptide developed at the same institutes and marketed for cognitive and neuroprotective indications. The two are sometimes combined in a single formulation aimed at balancing calm and mental sharpness.

The mechanistic rationale for cognitive effects centers on the same pathways described earlier. By modulating monoamine neurotransmitters, influencing BDNF, and reducing the cognitive interference that anxiety itself produces, Selank could plausibly improve attention and working memory in stressed or anxious individuals. In practice, some of the perceived "nootropic" benefit may be an indirect consequence of lowering anxiety: when the mind is less preoccupied by worry, concentration and recall often improve.

Direct evidence for cognitive enhancement in healthy people is limited. Most cognition-related findings come from animal studies or from human populations with an underlying anxiety or asthenic condition, where improvements in attention accompany symptom relief. There is little rigorous data showing that Selank sharpens cognition in already-healthy adults, and claims of dramatic memory or IQ gains are not supported by the literature. As always, distinguishing marketing enthusiasm from measured evidence is essential.

Readers interested in how peptides are combined to target complementary outcomes — for example, pairing a calming peptide with a stimulating one — can review our guide to peptide stacking. It is worth stressing that stacking multiplies unknowns: interactions between research peptides are poorly characterized, and combining compounds without medical supervision increases risk rather than simply adding benefits.

Because Selank descends from tuftsin — an immunomodulatory peptide — it has also been studied for effects beyond the brain. Tuftsin itself stimulates phagocytosis and modulates immune cell activity, and Selank appears to retain some of these properties. Research has reported that Selank can influence the expression of cytokines such as interleukin-6 (IL-6) and shift the balance of immune signaling, which has led to interest in its potential immunomodulatory and anti-inflammatory roles.

Some Russian studies have explored an antiviral dimension, examining whether Selank's immune effects could support the body's response to certain viral infections, including influenza. These investigations are preliminary and should not be read as evidence that Selank treats or prevents any infection. No regulatory agency has approved it for antiviral use, and extrapolating from early immunological findings to clinical outcomes would be premature.

Selank has additionally been examined for effects on stress physiology, including markers related to the hypothalamic-pituitary-adrenal (HPA) axis, and for possible antidepressant-adjacent properties tied to its serotonergic effects. The recurring theme across these studies is that Selank behaves as a broad regulatory peptide, nudging several biological systems toward balance rather than forcing a single dramatic change. This is consistent with its low effective doses and its favorable tolerability in the reports available.

As with the anxiolytic and cognitive data, these secondary applications rest on preclinical and small-scale human research. They are scientifically interesting and worth continued study, but they do not currently justify using Selank as an immune or antiviral product. The gap between mechanistic plausibility and proven clinical benefit remains wide, and honest interpretation requires keeping that gap in view.

In its Russian pharmaceutical form, Selank is delivered as an intranasal solution. The nasal route is favored because peptides are poorly absorbed when swallowed — digestive enzymes break them down before they reach the bloodstream — and because the nasal mucosa offers relatively direct access to the central nervous system. Intranasal dosing also avoids injections, which improves practicality and comfort.

Published dosing in the clinical and research literature has typically fallen in the range of roughly 250 to 900 micrograms per day, often divided across the day and administered as nasal drops or spray. Some protocols express dosing relative to body weight. The table below summarizes commonly referenced patterns for educational reference only; it is not a recommendation or a prescription.

Reconstitution matters for anyone handling a research vial of lyophilized (freeze-dried) peptide, since powder must be dissolved in an appropriate solvent such as bacteriostatic water before use. Errors in reconstitution are a common source of inaccurate dosing. A tool such as our peptide reconstitution calculator can help with the arithmetic of turning a milligram vial into a precise concentration, though it does not address whether use is advisable in the first place.

Because Selank is not an approved medication in most jurisdictions, there is no standardized, regulator-sanctioned dosing guidance outside Russia. Product purity, concentration, and labeling accuracy vary between suppliers, which introduces real uncertainty into any self-directed protocol. This is one more reason that decisions about dosing should involve a qualified healthcare professional rather than relying on forum consensus or vendor instructions.

In the studies available, Selank has shown a favorable tolerability profile. A defining feature is the apparent absence of the problems that limit benzodiazepines: reports do not describe sedation, cognitive dulling, tolerance, physical dependence, or a withdrawal syndrome on discontinuation. This clean profile is one of the main reasons the peptide attracts interest as a potential alternative anxiolytic.

Reported side effects are generally mild. Because the peptide is given intranasally, the most commonly mentioned complaints involve local nasal irritation or discomfort. Occasional reports mention transient changes in blood pressure, mild fatigue, or altered taste, but serious adverse events are uncommon in the published literature. It is important to recognize that this reassuring picture is based largely on short courses and relatively small populations; the long-term safety of extended or repeated use has not been well characterized.

Several groups face elevated uncertainty and should be especially cautious. There is insufficient safety data for pregnant or breastfeeding individuals, for adolescents and children, and for people with significant psychiatric or medical conditions or those taking other central nervous system medications. Potential interactions with antidepressants, sedatives, or other neuroactive drugs have not been thoroughly studied, and combining Selank with such medications without oversight could carry unpredictable risks.

A practical safety concern that has nothing to do with the molecule itself is product quality. Peptides sold for research use are not manufactured to pharmaceutical standards, and independent testing has repeatedly found variability in purity and content across the broader research-peptide market. Contaminants, incorrect dosing, and mislabeling are genuine hazards. For a fuller discussion of the general risks that apply to this category, see our medical disclaimer. None of the information here should be taken as medical advice; anyone considering Selank should discuss it with a licensed clinician first.

Selank occupies an unusual regulatory position. In Russia, it has been registered and is available as an anxiolytic medication. In most of the rest of the world, however, it holds no such status: it is not approved by the FDA or the EMA, and it is neither a recognized dietary supplement nor an authorized drug in the United States or the European Union. Where it is sold internationally, it is almost always labeled "for research use only," a designation that explicitly excludes human consumption.

This means legal status varies substantially by jurisdiction, and buyers bear responsibility for understanding their local laws. In some countries importing or possessing research peptides sits in a legal gray zone; in others it may be restricted. Selank is not currently a controlled substance in the United States, but "not scheduled" is not the same as "approved for use." Athletes should also note that peptides are scrutinized by anti-doping bodies, and the regulatory landscape can change.

On the supply side, Selank is offered by several research-chemical vendors, usually as a lyophilized powder in vials of a few milligrams. As a reference point from current supplier listings, SwissChems lists Selank 5 mg at $25.95 per vial (and a 10-vial kit at $259.50), while AminoClub lists Selank at $31.99; AminoClub ships within the United States only. There is also a combined Semax + Selank blend available from EU-focused suppliers for those interested in the paired nootropic-anxiolytic approach. Prices and availability change frequently, so always confirm the current figure on the supplier's own site before relying on it.

When evaluating any source, prioritize vendors that publish third-party certificates of analysis (COAs) confirming identity and purity, since the research-peptide market is uneven and unregulated. To put Selank in context alongside other widely discussed peptides, our guides on BPC-157 and related compounds illustrate how research status, evidence quality, and legal standing differ from one peptide to the next. Ultimately, the responsible path is to treat Selank as an experimental compound: interesting, moderately studied, but not a proven or approved therapy, and never a substitute for professional medical care.